Bioasis


Home
		Network	Programs	Careers	Contact Us
	About Us		Investors Info		News

Our Company
biOasis Technologies Inc. (TSX-V:BTI) is a publically traded biopharmaceutical company focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system (“CNS”) diseases and disorders. Of particular interest is the creation of therapeutic options for patient management to address the limitations to biodistribution presented by the properties of the blood-brain barrier (“BBB”).

Our Business Strategy
BTI’s business strategy emphasizes out-licensing its technologies to qualified partners, and strategic acquisitions of products and technologies relevant to the diagnosis and management of CNS diseases and disorders.

For more about our current development programs click here…

January 16, 2012
biOasis Enters Investor Relations Agreement with Brisco Capital Partners Corp.
biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) – is pleased to announce that it has Brisco Capital Partners Corp. (“Brisco”) to provide investor relations, subject to regulatory approval. Brisco will initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and its activities. Brisco takes a full service approach to investor relations and provides creative investor relations’ programs for Canadian public companies.
Read More... >>

Upcoming Events

Subscribe to our mailing list